80.48 USD
-0.19 (-0.24%)
MLAB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While MLAB is still in line with the averages on profitability rating, there are concerns on its financial health. MLAB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year MLAB has reported negative net income.
In the past year MLAB had a positive cash flow from operations.
In multiple years MLAB reported negative net income over the last 5 years.
MLAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.37%, MLAB is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Looking at the Return On Equity, with a value of -0.88%, MLAB is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
MLAB has a better Return On Invested Capital (3.11%) than 64.91% of its industry peers.
MLAB had an Average Return On Invested Capital over the past 3 years of 2.10%. This is significantly below the industry average of 13.99%.
The last Return On Invested Capital (3.11%) for MLAB is above the 3 year average (2.10%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROIC | 3.11% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
1.3 Margins
MLAB's Operating Margin of 6.13% is fine compared to the rest of the industry. MLAB outperforms 61.40% of its industry peers.
In the last couple of years the Operating Margin of MLAB has grown nicely.
MLAB has a better Gross Margin (62.15%) than 82.46% of its industry peers.
MLAB's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% |
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
The number of shares outstanding for MLAB has been increased compared to 1 year ago.
Compared to 5 years ago, MLAB has more shares outstanding
The debt/assets ratio for MLAB has been reduced compared to a year ago.
2.2 Solvency
MLAB has an Altman-Z score of 1.29. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MLAB (1.29) is worse than 61.40% of its industry peers.
The Debt to FCF ratio of MLAB is 4.69, which is a neutral value as it means it would take MLAB, 4.69 years of fcf income to pay off all of its debts.
MLAB has a Debt to FCF ratio of 4.69. This is in the better half of the industry: MLAB outperforms 71.93% of its industry peers.
A Debt/Equity ratio of 0.95 indicates that MLAB is somewhat dependend on debt financing.
MLAB has a worse Debt to Equity ratio (0.95) than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Altman-Z | 1.29 |
ROIC/WACC0.3
WACC10.49%
2.3 Liquidity
MLAB has a Current Ratio of 2.02. This indicates that MLAB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.02, MLAB perfoms like the industry average, outperforming 40.35% of the companies in the same industry.
MLAB has a Quick Ratio of 1.44. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
MLAB has a Quick ratio of 1.44. This is in the lower half of the industry: MLAB underperforms 61.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for MLAB have decreased strongly by -104.68% in the last year.
MLAB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -39.16% yearly.
MLAB shows a small growth in Revenue. In the last year, the Revenue has grown by 7.39%.
Measured over the past years, MLAB shows a quite strong growth in Revenue. The Revenue has been growing by 15.41% on average per year.
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
3.2 Future
Based on estimates for the next years, MLAB will show a very strong growth in Earnings Per Share. The EPS will grow by 231.94% on average per year.
MLAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.49% yearly.
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
MLAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 49.42 indicates a quite expensive valuation of MLAB.
MLAB's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of MLAB to the average of the S&P500 Index (24.03), we can say MLAB is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.42 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MLAB is valued cheaper than 87.72% of the companies in the same industry.
MLAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MLAB is cheaper than 98.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.91 | ||
| EV/EBITDA | 15.05 |
4.3 Compensation for Growth
MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MLAB may justify a higher PE ratio.
MLAB's earnings are expected to grow with 231.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y382.35%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
MLAB has a yearly dividend return of 0.79%, which is pretty low.
MLAB's Dividend Yield is rather good when compared to the industry average which is at 0.09. MLAB pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 1.88, MLAB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
MLAB has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-222.26%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
NASDAQ:MLAB (12/26/2025, 12:19:46 PM)
80.48
-0.19 (-0.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.58%
Inst Owner Change-11.9%
Ins Owners5.47%
Ins Owner Change3.69%
Market Cap444.25M
Revenue(TTM)245.25M
Net Income(TTM)-1.57M
Analysts80
Price Target96.9 (20.4%)
Short Float %5.37%
Short Ratio2.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-222.26%
Div Incr Years0
Div Non Decr Years21
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)133.29%
Min EPS beat(2)90.84%
Max EPS beat(2)175.74%
EPS beat(4)2
Avg EPS beat(4)-16.43%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)416.54%
EPS beat(12)5
Avg EPS beat(12)215.06%
EPS beat(16)7
Avg EPS beat(16)156.44%
Revenue beat(2)0
Avg Revenue beat(2)-2.79%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-1.95%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.93%
Revenue beat(16)6
Avg Revenue beat(16)0.23%
PT rev (1m)7.34%
PT rev (3m)7.34%
EPS NQ rev (1m)7.79%
EPS NQ rev (3m)-6.74%
EPS NY rev (1m)9.16%
EPS NY rev (3m)3.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.46%
Revenue NY rev (1m)-0.4%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.42 | ||
| P/S | 1.81 | ||
| P/FCF | 11.91 | ||
| P/OCF | 10.78 | ||
| P/B | 2.49 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.05 |
EPS(TTM)-0.27
EYN/A
EPS(NY)1.63
Fwd EY2.02%
FCF(TTM)6.76
FCFY8.4%
OCF(TTM)7.47
OCFY9.28%
SpS44.43
BVpS32.33
TBVpS-18.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROCE | 3.94% | ||
| ROIC | 3.11% | ||
| ROICexc | 3.28% | ||
| ROICexgc | 14.87% | ||
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% | ||
| FCFM | 15.21% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 15.81% | ||
| Cap/Sales | 1.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.29 |
F-Score5
WACC10.49%
ROIC/WACC0.3
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
EBIT growth 1Y22.54%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year177.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y2.55%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y3.18%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
Can you provide the valuation status for MESA LABORATORIES INC?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
Is the dividend of MESA LABORATORIES INC sustainable?
The dividend rating of MESA LABORATORIES INC (MLAB) is 4 / 10 and the dividend payout ratio is -222.26%.